Effect of liver biopsy size on MASLD fibrosis assessment by second-harmonic generation/two-photon excitation fluorescence microscopy

QR Code

Effect of liver biopsy size on MASLD fibrosis assessment by second-harmonic generation/two-photon excitation fluorescence microscopy

Background & Aims: Fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD) is a prognostic indicator and clinical trial efficacy endpoint. Second-harmonic generation/two-photon excitation fluorescence (SHG/TPEF) microscopy images unstained tissue sections and, when integ...

Full description

Saved in:

Bibliographic Details
Main Authors:	Daniel T. Field, Yayun Ren, Kutbuddin Akbary, Elaine Chng, Dean Tai, Nikolai V. Naoumov, David E. Kleiner, Jonathan A. Fallowfield, Timothy J. Kendall, Arun J. Sanyal
Format:	Article
Language:	English
Published:	Elsevier 2025-08-01
Series:	JHEP Reports
Subjects:	Humans Metabolic dysfunction-associated steatotic liver disease Non-alcoholic fatty liver disease Liver cirrhosis Biopsy Artificial intelligence
Online Access:	http://www.sciencedirect.com/science/article/pii/S2589555925001272
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Pathogenic aspects of fructose consumption in metabolic dysfunction-associated steatotic liver disease (MASLD): A narrative review
by: Katharina Burger, et al.
Published: (2025-06-01)

Impact of myokines on chronic liver diseases: exploring the effects of metabolic dysfunction-associated steatotic liver disease (MASLD) on skeletal muscle. A narrative review
by: Francisco Aguirre, et al.
Published: (2025-07-01)

Steatotic Liver Disease: New Nomenclature and Its Localization in the Russian Federation
by: K. L. Raikhelson, et al.
Published: (2024-05-01)

Sex disparities in alcohol-associated liver disease and subtype differences in alcohol-attributable cancers in the United States
by: Pojsakorn Danpanichkul, et al.
Published: (2025-07-01)

Non-invasive methods for diagnosing portal hypertension and variceal bleeding due to liver cirrhosis secondary to NAFLD/MASLD: systematic review
by: Nebyu Yonas Shanka, et al.
Published: (2025-01-01)

Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study
by: Xianhua Mao, et al.
Published: (2025-07-01)

Differential Expression of Lipid Metabolism Genes, CROT and ABCG1, in Obese Patients with Comorbid Depressive Disorder and Risk of MASLD
by: Joanna Michalina Jurek, et al.
Published: (2025-06-01)

New steatotic liver disease criteria diagnostic performance in an agricultural population in Chile
by: Maria Spencer-Sandino, et al.
Published: (2025-07-01)

Metabolic Dysfunction–Associated Steatotic Liver Disease, Alcohol Consumption, and the Risk of Atrial Fibrillation: A Nationwide Population‐Based Study
by: Minkwan Kim, et al.
Published: (2025-07-01)

GCKR Polymorphisms Increase the Risks of Low Bone Mineral Density in Young and Non‐Obese Patients With MASLD and Hyperuricemia
by: Tzu‐Hao Li, et al.
Published: (2025-06-01)

Adaptation using IM Adapt of an evidence-based lifestyle intervention to support the management of metabolic-dysfunction associated steatotic liver disease among Hispanic/Latino adults
by: Natalia I. Heredia, et al.
Published: (2025-07-01)

Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease
by: Hye Won Lee, et al.
Published: (2025-07-01)

What is new in the 2024 Chinese guidelines for fatty liver disease?
by: Rui-Xu Yang, et al.
Published: (2025-07-01)

Metabolic Dysfunction-Associated Steatotic Liver Disease: From a Very Low-Density Lipoprotein Perspective
by: Yan Chen, et al.
Published: (2025-07-01)

The evolution of international definitions of fatty liver disease and insights into the working definition and features of the 2024 Chinese guideline
by: Li CHEN, et al.
Published: (2025-06-01)

Letter to the editor on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”
by: Weixiong Zhu, et al.
Published: (2025-07-01)

Phosphatidylethanol and ethyl glucuronide to categorize alcohol consumption in alcohol-related cirrhosis
by: Benedict T.K. Vanlerberghe, et al.
Published: (2025-08-01)

From cooperation to collapse: systemic failure in liver disease through a sociological lens
by: Junyu Wang, et al.
Published: (2025-07-01)

Adherence to a “MediterrAsian” diet is associated with weight loss-independent improvements in liver fat and lipid profile, but not glucoregulation or inflammation: secondary analysis of a randomized controlled trial
by: Yu Chung Chooi, et al.
Published: (2025-07-01)

The Role of "Biotics" in the Modulation of the Intestinal Microbiota in Metabolic-Associated Steatotic Liver Disease
by: G. Fadieienko, et al.
Published: (2025-03-01)

Interventions targeting the gut-liver axis: A potential treatment strategy for metabolic dysfunction-associated steatotic liver disease
by: Pingping Jin, et al.
Published: (2025-07-01)

Metabolic dysfunction-associated steatotic liver disease (MASLD): emerging insights into gut microbiota interactions and therapeutic perspectives
by: Wenchu Qian, et al.
Published: (2025-06-01)

Comparing FIB-4, VCTE, pSWE, 2D-SWE, and MRE Thresholds and Diagnostic Accuracies for Detecting Hepatic Fibrosis in Patients with MASLD: A Systematic Review and Meta-Analysis
by: Mitchell Patrick Wilson, et al.
Published: (2025-06-01)

Metabolic and inflammatory links between metabolic dysfunction-associated steatotic liver disease and Alzheimer's disease
by: Gary Zhang
Published: (2025-04-01)

Association of estimated glucose disposal rate with risk of future metabolic dysfunction-associated steatotic liver disease and other chronic liver diseases: a prospective cohort study
by: Yan Li, et al.
Published: (2025-07-01)

EAT-Lancet diet and risk of metabolic dysfunction-associated steatotic liver disease and other liver chronic diseases: a large prospective cohort study in the UK Biobank
by: Shi-Yi Wu, et al.
Published: (2025-07-01)

Update of machine learning for ultrasound diagnosis of metabolic dysfunction-associated steatotic liver disease: a bright future for deep learning
by: Jiawen Li, et al.
Published: (2025-06-01)

Treatment with pemafibrate ameliorates fatty liver index and atherogenic lipid profiles in Japanese patients with type 2 diabetes mellitus
by: Toru Suzuki, et al.
Published: (2025-07-01)

Phocaeicola dorei ameliorates progression of steatotic liver disease by regulating bile acid, lipid, inflammation and proliferation
by: Jieun Choi, et al.
Published: (2025-12-01)

Emerging therapies and real-world application of metabolic dysfunction-associated steatotic liver disease treatment
by: Hee Yeon Kim, et al.
Published: (2025-07-01)

Regulatory Mechanisms of Phenolic Acids in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review
by: Shengyu Zhang, et al.
Published: (2025-06-01)

Serum insulin-like growth factor binding protein 2 is associated with hepatic steatosis in adults with metabolic dysfunction-associated steatotic liver disease
by: Ziwei Wang, et al.
Published: (2025-07-01)

Association of Metabolic Dysfunction‐Associated Steatotic Liver Disease With Sudden Sensorineural Hearing Loss Among Older Adults
by: Eun Seok Kang, et al.
Published: (2025-06-01)

Impact of the growth hormone and IGF-1 on graft function and immune response in pediatric liver recipients
by: R. M. Kurabekova, et al.
Published: (2022-07-01)

Current and Emerging Treatments for Metabolic Associated Steatotic Liver Disease and Diabetes: A Narrative Review
by: Rachelle Choi, et al.
Published: (2025-06-01)

Association of Serum Selenium with Clinical Features and Inflammatory and Oxidative Stress Markers in Iranian Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease—A Cross-Sectional Study
by: Abbas Pishdadian, et al.
Published: (2025-06-01)

Serum Osteopontin and Procollagen Type 1 N-Terminal Propeptide Concentrations: Links to Liver Function, Muscle Mass, and Bone Mineral Density in MASLD and Hypertension
by: Anna F. Sheptulina, et al.
Published: (2025-07-01)

Efficacy and Safety of Bicyclol Treatment for Non-Alcoholic Fatty Liver Disease: Results of a Cohort Study
by: I. Yu. Pirogova, et al.
Published: (2018-09-01)

Modern Possibilities of Endosurgical Biopsy in Children with Chronic Liver Diseases
by: Polina V. Khrolenko, et al.
Published: (2018-07-01)

THE ROLE OF CRYOSURGICAL SURGICAL MEASURES DURING ALVEOLAR LIVER DISEASE REOPERATIONS
by: B. I. Alperovich, et al.
Published: (2017-01-01)